10th Late Phase Research and Real-World Data

22-23 May 2014, Dublin, Ireland

The 10th Late Phase Research/Real-World Data conference combines two important topics into one comprehensive platform.
More info >>

Reinventing Buffer Screening with Avacta’s Optim Technology

Avacta’s Optim protein stability analysis technology is helping researchers at Manchester University to approach buffer selection in an entirely new way. Dr Tom Jowitt, Manager of the University’s Biomolecular Analysis Core Facility, explained: “Academic institutions tend to work by word of mouth on protein projects, sticking to buffer conditions they are familiar with, or that have been used on previous projects within the laboratory. The buffers in use are often far from optimal for the protein of interest, but a lack of understanding of how to optimise buffer conditions means that these issues are rarely addressed.”
More info >>

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>